NASDAQ · Biotechnology
TGTX (TGTX) Stock
$52.17
-2.54%
NASDAQ: TGTX
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
TGTX: Lowering target price to $60.00
Argus Research · Jul 15, 2026
TG Therapeutics (TGTX) Gains as Its Key Drug Exceeded Expectations
Insider Monkey · Jul 13, 2026
TG Therapeutics (TGTX) Starts Phase 2 Briumvi Trial
Insider Monkey · Jul 9, 2026
TG Therapeutics (TGTX) Stock May Still Be Cheap Despite New Trial News
Simply Wall St. · Jul 9, 2026
2 Fast-Growing Pharmaceutical Stocks to Buy Now
Motley Fool · Jul 9, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held7.47%
Institutions Held70.25%
Institutions Float Held75.92%
Peer Comparison
About TGTX
TGTX is led by CEO Michael S. Weiss, employs 399 people, headquartered in Morrisville, US, publicly traded since 2010.
TGTX stock trades at $52.17 with a market capitalization of $7.99B. The stock is valued at a price-to-earnings (P/E) ratio of 17.51, price-to-book of 12.17, price-to-sales of 10.95. Over the past 52 weeks the stock has ranged between $25.28 and $59.06, and currently trades 11.7% below its 52-week high.
On profitability, TGTX generates a return on equity (ROE) of 112.60% — well above the market average, a sign of a high-quality business, return on capital employed of 18.98%, an operating margin of 21.35%, a net profit margin of 65.95%.